Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan, which is in Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. Phathom Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Florham Park, New Jersey.
Revenue of Phathom Pharmaceuticals, Inc. (PHAT)
Revenue in 2023 (TTM): $682 K
According to Phathom Pharmaceuticals, Inc.'s latest financial reports the company's current revenue (TTM) is $682 K. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history of Phathom Pharmaceuticals, Inc.
Annual Revenue
| Year | Revenue | Gross Profit | Ebitda | Income Before Tax | Net Income |
|---|---|---|---|---|---|
| 2023 | $682 K | $515 K | $-159,049,000 | $-201,592,000 | $-201,592,000 |
| 2022 | $ | $-620,000 | $-171,820,000 | $-197,723,000 | $-223,006,000 |
| 2021 | $ | $-521,000 | $-134,559,000 | $-143,883,000 | $-148,094,000 |
| 2020 | $ | $-300,000 | $-124,187,000 | $-129,068,000 | $-133,318,000 |
| 2019 | $ | $-8,000 | $-250,946,000 | $-255,131,000 | $-209,744,000 |
| 2018 | $ | $ | $-50,000 | $-1,288,000 | $-1,288,000 |